SHR-1701 + paclitaxel + cisplatin + carboplatin + bevacizumab

SHR-1701 + paclitaxel + cisplatin + carboplatin + bevacizumab is an **experimental multi-agent combination regimen** primarily investigated in clinical trials for advanced, locally resectable, or metastatic cancers such as esophageal squamous cell carcinoma (ESCC) and potentially other solid tumors. SHR-1701 is a bifunctional fusion protein combining a monoclonal antibody against programmed death-ligand 1 (PD-L1) with the extracellular domain of transforming growth factor-beta receptor II (TGF-βRII), targeting both immune checkpoint inhibition and TGF-β signaling. Paclitaxel, cisplatin, and carboplatin are established cytotoxic chemotherapeutic agents. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), inhibiting tumor angiogenesis. The combination is designed to synergistically target tumor proliferation, immune evasion, and angiogenesis for improved antitumor effects in unresectable or advanced-stage cancers[1][3][5].